Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34523
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18055/20253 (89%)
造访人次 : 175223      在线人数 : 570
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34523


    標題: Upregulation of peroxisome proliferator-activated receptor-alpha and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer
    作者: Wang, Chih-Yang
    Chao, Ying-Jui
    Chen, Yi-Ling
    Wang, Tzu-Wen
    Phan, Nam Nhut
    Hsu, Hui-Ping
    Shan, Yan-Shen
    Lai, Ming-Derg
    貢獻者: Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery
    Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery
    Natl Cheng Kung Univ, Dept Surg, Coll Med, Natl Cheng Kung Univ Hosp
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    Chia Nan Univ Pharm & Sci, Senior Citizen Serv Management
    Nguyen Tat Tharth Univ, NTT Inst Hi Technol
    Vanderbilt Univ, Dept Biostat, Med Ctr, Nashville
    Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol
    Natl Cheng Kung Univ, Inst Basic Med Sci
    Natl Cheng Kung Univ, Coll Med, Ctr Infect Dis & Signaling Res
    關鍵字: Ampullary cancer
    Lipid metabolism
    Carcinogenesis
    PPARA gene
    Bioinformatics
    日期: 2021
    上傳時間: 2023-11-11 12:00:55 (UTC+8)
    出版者: IVYSPRING INT PUBL
    摘要: Ampullary cancer is a rare periampullary cancer currently with no targeted therapeutic agent. It is important to develop a deeper understanding of the carcinogenesis of ampullary cancer. We attempted to explore the characteristics of ampullary cancer in our dataset and a public database, followed by a search for potential drugs. We used a bioinformatics pipeline to analyze complementary (c)DNA microarray data of ampullary cancer and surrounding normal duodenal tissues from five patients. A public database from the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) was applied for external validation. Bioinformatics tools used included the Gene Set Enrichment Analysis (GSEA), Database for Annotation, Visualization and Integrated Discovery (DAVID), MetaCore, Kyoto Encyclopedia of Genes and Genomes (KEGG), Hallmark, BioCarta, Reactome, and Connectivity Map (CMap). In total, 9097 genes were upregulated in the five ampullary cancer samples compared to normal duodenal tissues. From the MetaCore analysis, genes of peroxisome proliferator-activated receptor alpha (PPARA) and retinoid X receptor (RXR)-regulated lipid metabolism were overexpressed in ampullary cancer tissues. Further a GSEA of the KEGG, Hallmark, Reactome, and Gene Ontology databases revealed that PPARA and lipid metabolism-related genes were enriched in our specimens of ampullary cancer and in the NCBI GSE39409 database. Expressions of PPARA messenger (m)RNA and the PPAR-alpha protein were higher in clinical samples and cell lines of ampullary cancer. US Food and Drug Administration (FDA)-approved drugs, including alvespimycin, trichostatin A (a histone deacetylase inhibitor), and cytochalasin B, may have novel therapeutic effects in ampullary cancer patients as predicted by the CMap analysis. Trichostatin A was the most potent agent for ampullary cancer with a half maximal inhibitory concentration of < 0.3 mu M. According to our results, upregulation of PPARA and lipid metabolism-related genes are potential pathways in the carcinogenesis and development of ampullary cancer. Results from the CMap analysis suggested potential drugs for patients with ampullary cancer.
    關聯: INT J MED SCI, v.18, n.1, pp.256-269
    显示于类别:[高齡福祉養生管理系] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ijms.48123.pdf3107KbAdobe PDF64检视/开启
    index.html0KbHTML227检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈